{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T06:11:48Z","timestamp":1789279908518,"version":"build-2803163510"},"reference-count":19,"publisher":"Walter de Gruyter GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"Abstract<\/jats:title>\n \n Objectives<\/jats:title>\n Adolescent obesity is associated with increased rates of depression and suicidality. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used to treat pediatric obesity, yet concerns remain regarding potential psychiatric effects. This study evaluated changes in depressive symptoms and suicidality screening scores among adolescents with obesity treated with GLP-1RAs in a pediatric endocrinology setting. We evaluated changes in depressive symptoms and suicidality following initiation of GLP-1RA therapy in adolescents with obesity.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We performed a retrospective chart review of adolescents aged 12\u201321\u00a0years with obesity treated with liraglutide or semaglutide at a single academic center between June 2022 and December 2024. Demographic, clinical, and psychosocial data were extracted from the electronic health record at baseline and follow-up. Depressive symptoms or suicidality were screened at clinic visits per protocol using either the Patient Health Questionnaire-9 (PHQ-9) or the Ask Suicide-Screening Questions (ASQ), respectively. Analyses were restricted to patients with paired baseline and follow-up assessments using the same instrument. Paired nonparametric tests were used for longitudinal comparisons.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Forty-four adolescents met inclusion criteria. Among patients with paired PHQ-9 data (n=15), the median PHQ-9 score decreased significantly from 6 (IQR 2\u201314) at baseline to 1 (IQR 0\u20135) at follow-up (p=0.003), independent of changes in BMI. Among patients with paired ASQ data (n=23), no increase in suicidality or new suicidal ideation was observed.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In this small, exploratory retrospective review, no evidence of short-term psychological harm or increased suicidality was observed among adolescents receiving GLP-1RA therapy. These findings support the short-term psychosocial safety of GLP-1RA therapy in adolescents with obesity. Larger prospective case\u2013control studies are needed to better characterize psychiatric safety and psychosocial outcomes.<\/jats:p>\n <\/jats:sec>","DOI":"10.1515\/jpem-2026-0227","type":"journal-article","created":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T05:55:40Z","timestamp":1789278940000},"source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 receptor agonist use and mental health outcomes in adolescents with obesity: a retrospective review"],"prefix":"10.1515","author":[{"given":"Jeries","family":"Said","sequence":"first","affiliation":[{"name":"Department of Pediatric Endocrinology , Medical College of Wisconsin , Milwaukee , WI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melodee","family":"Liegl","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Bioinformatics and Quantitative Child Health , Medical College of Wisconsin , Milwaukee , WI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy Y.","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Bioinformatics and Quantitative Child Health , Medical College of Wisconsin , Milwaukee , WI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Dabrowski","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology , Medical College of Wisconsin , Milwaukee , WI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"2026091305553657439_j_jpem-2026-0227_ref_001","doi-asserted-by":"crossref","unstructured":"Weghuber, D, Barrett, T, Barrientos-P\u00e9rez, M, Gies, I, Hesse, D, Jeppesen, OK, et al.. Once-weekly semaglutide in adolescents with obesity. N\u00a0Engl J Med 2022;387:2245\u201357. https:\/\/doi.org\/10.1056\/nejmoa2208601.","DOI":"10.1056\/NEJMoa2208601"},{"key":"2026091305553657439_j_jpem-2026-0227_ref_002","doi-asserted-by":"crossref","unstructured":"Kelly, AS, Auerbach, P, Barrientos-P\u00e9rez, M, Gies, I, Hale, PM, Marcus, C, et al.. A randomized, controlled trial of liraglutide for adolescents with obesity. N\u00a0Engl J Med 2020;382:2117\u201328. https:\/\/doi.org\/10.1056\/nejmoa1916038.","DOI":"10.1056\/NEJMoa1916038"},{"key":"2026091305553657439_j_jpem-2026-0227_ref_003","doi-asserted-by":"crossref","unstructured":"D\u0119bski, J, Przyby\u0142owski, J, Skibiak, K, Czerwi\u0144ska, M, Wal\u0119dziak, M, R\u00f3\u017ca\u0144ska-Wal\u0119dziak, A. Depression and obesity-do we know everything about it? A narrative review. Nutrients 2024;16:3383. https:\/\/doi.org\/10.3390\/nu16193383.","DOI":"10.3390\/nu16193383"},{"key":"2026091305553657439_j_jpem-2026-0227_ref_004","doi-asserted-by":"crossref","unstructured":"Ebrahimi, P, Batlle, JC, Ayati, A, Maqsood, MH, Long, C, Tarabanis, C, et al.. Suicide and self-harm events with GLP-1 receptor agonists in adults with diabetes or obesity: a systematic review and meta-analysis. JAMA Psychiatry 2025;82:888\u201395. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.0091.","DOI":"10.1001\/jamapsychiatry.2025.0091"},{"key":"2026091305553657439_j_jpem-2026-0227_ref_005","doi-asserted-by":"crossref","unstructured":"Sa, B, Maristany, A, Subramaniam, A, Guillen, R, Buonocore, B, Smith, A, et al.. Psychiatric effects of GLP-1 receptor agonists: a systematic\u00a0review of emerging evidence. Diabetes Obes Metabol 2026;28:50\u20139. https:\/\/doi.org\/10.1111\/dom.70198.","DOI":"10.1111\/dom.70198"},{"key":"2026091305553657439_j_jpem-2026-0227_ref_006","doi-asserted-by":"crossref","unstructured":"O\u2019Connor, EA, Evans, CV, Henninger, M, Redmond, N, Senger, CA. Interventions for weight management in children and adolescents: updated evidence report and systematic review for the US preventive services task force. JAMA 2024;332:233\u201348. https:\/\/doi.org\/10.1001\/jama.2024.6739.","DOI":"10.1001\/jama.2024.6739"},{"key":"2026091305553657439_j_jpem-2026-0227_ref_007","doi-asserted-by":"crossref","unstructured":"Hannon, TS, Chao, LC, Barrientos-P\u00e9rez, M, Pamidipati, KC, Fern\u00e1ndez Land\u00f3, L, Lee, CJ, et al.. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2025;406:1484\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(25)01774-X.","DOI":"10.1016\/S0140-6736(25)01774-X"},{"key":"2026091305553657439_j_jpem-2026-0227_ref_008","doi-asserted-by":"crossref","unstructured":"Anderberg, RH, Richard, JE, Hansson, C, Nissbrandt, H, Bergquist, F, Skibicka, KP. GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. Psychoneuroendocrinology 2016;65:54\u201366. https:\/\/doi.org\/10.1016\/j.psyneuen.2015.11.021.","DOI":"10.1016\/j.psyneuen.2015.11.021"},{"key":"2026091305553657439_j_jpem-2026-0227_ref_009","doi-asserted-by":"crossref","unstructured":"Lincoff, AM, Brown-Frandsen, K, Colhoun, HM, Deanfield, J, Emerson, SS, Esbjerg, S, et al.. Semaglutide and cardiovascular outcomes in obesity without diabetes. N\u00a0Engl J Med 2023;389:2221\u201332. https:\/\/doi.org\/10.1056\/nejmoa2307563.","DOI":"10.1056\/NEJMoa2307563"},{"key":"2026091305553657439_j_jpem-2026-0227_ref_010","doi-asserted-by":"crossref","unstructured":"McIntyre, RS, Mansur, RB, Rosenblat, JD, Kwan, ATH. The association between glucagon-like peptide-1 receptor agonists and suicidality: reports to the food and drug administration adverse event reporting system. Expert Opin Drug Saf 2024;23:47\u201355. https:\/\/doi.org\/10.1080\/14740338.2023.2295397.","DOI":"10.1080\/14740338.2023.2295397"},{"key":"2026091305553657439_j_jpem-2026-0227_ref_011","doi-asserted-by":"crossref","unstructured":"Schoretsanitis, G, Weiler, S, Barbui, C, Raschi, E, Gastaldon, C. Disproportionality analysis from world health organization data on semaglutide, liraglutide, and suicidality. JAMA Netw Open 2024;7:e2423385. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.23385.","DOI":"10.1001\/jamanetworkopen.2024.23385"},{"key":"2026091305553657439_j_jpem-2026-0227_ref_012","doi-asserted-by":"crossref","unstructured":"Wang, M, Yang, Z, Yan, M, Liu, S, Xiao, S. Depression and suicide\/self-injury signals for weight loss medications: a disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database. J\u00a0Affect Disord 2025;389:119670. https:\/\/doi.org\/10.1016\/j.jad.2025.119670.","DOI":"10.1016\/j.jad.2025.119670"},{"key":"2026091305553657439_j_jpem-2026-0227_ref_013","doi-asserted-by":"crossref","unstructured":"Chen, J, Zhang, Q, Wu, Q, Zhang, X, Xiang, Z, Zhu, S, et al.. Impact of GLP-1 receptor agonists on suicide behavior: a meta-analysis based on randomized controlled trials. J\u00a0Diabetes 2025;17:e70151. https:\/\/doi.org\/10.1111\/1753-0407.70151.","DOI":"10.1111\/1753-0407.70151"},{"key":"2026091305553657439_j_jpem-2026-0227_ref_014","doi-asserted-by":"crossref","unstructured":"Ueda, P, S\u00f6derling, J, Wintzell, V, Svanstr\u00f6m, H, Pazzagli, L, Eliasson, B, et al.. GLP-1 receptor agonist use and risk of suicide death. JAMA Intern Med 2024;184:1301\u201312. https:\/\/doi.org\/10.1001\/jamainternmed.2024.4369.","DOI":"10.1001\/jamainternmed.2024.4369"},{"key":"2026091305553657439_j_jpem-2026-0227_ref_015","doi-asserted-by":"crossref","unstructured":"Ganeshalingam, AA, Uhrenholt, N, Arnfred, S, G\u00e6de, P, D\u00fcring, S, Stenager, EN, et al.. Semaglutide treatment of antipsychotic-treated patients with schizophrenia, prediabetes, and obesity: the HISTORI\u00a0randomized clinical trial. JAMA Psychiatry 2025;82:1065\u201374. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.2332.","DOI":"10.1001\/jamapsychiatry.2025.2332"},{"key":"2026091305553657439_j_jpem-2026-0227_ref_016","doi-asserted-by":"crossref","unstructured":"Fonseca-Pedrero, E, D\u00edez-G\u00f3mez, A, P\u00e9rez-Alb\u00e9niz, A, Al-Halab\u00ed, S, Lucas-Molina, B, Debban\u00e9, M. Youth screening depression: validation of the patient health Questionnaire-9 in a representative sample of adolescents. Psychiatry Res 2023;328:115486. https:\/\/doi.org\/10.1016\/j.psychres.2023.115486.","DOI":"10.1016\/j.psychres.2023.115486"},{"key":"2026091305553657439_j_jpem-2026-0227_ref_017","doi-asserted-by":"crossref","unstructured":"Aguinaldo, LD, Sullivant, S, Lanzillo, EC, Ross, A, He, JP, Bradley-Ewing, A, et al.. Validation of the ask suicide-screening questions with youth in outpatient specialty and primary care clinics. Gen Hosp Psychiatry 2021;68:52\u20138. https:\/\/doi.org\/10.1016\/j.genhosppsych.2020.11.006.","DOI":"10.1016\/j.genhosppsych.2020.11.006"},{"key":"2026091305553657439_j_jpem-2026-0227_ref_018","doi-asserted-by":"crossref","unstructured":"Tamborlane, WV, Barrientos-P\u00e9rez, M, Fainberg, U, Frimer-Larsen, H, Hafez, M, Hale, PM, et al.. Liraglutide in children and adolescents with type 2 diabetes. N\u00a0Engl J Med 2019;381:637\u201346. https:\/\/doi.org\/10.1056\/nejmoa1903822.","DOI":"10.1056\/NEJMoa1903822"},{"key":"2026091305553657439_j_jpem-2026-0227_ref_019","doi-asserted-by":"crossref","unstructured":"Cooper, DM, Rothstein, MA, Amin, A, Hirsch, JD, Cooper, E. Unintended consequences of glucagon-like peptide-1 receptor agonists medications in children and adolescents: a call to action. J\u00a0Clin Transl Sci 2023;7:e184. https:\/\/doi.org\/10.1017\/cts.2023.612.","DOI":"10.1017\/cts.2023.612"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2026-0227\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2026-0227\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T05:55:46Z","timestamp":1789278946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2026-0227\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":19,"alternative-id":["10.1515\/jpem-2026-0227"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2026-0227","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]}}}